The effect of intrathecal sufentanil on analgesia of gastrointestinal cancer surgeries

Use high dose of intrathecal sufentanil for intraoperative and postoperative pain relife in gastrointestinal cancers surgeries

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210129050174N1

Enrollment

Registered

2021-12-20

Start date

2021-05-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain relife in gastrointestinal cancers surgeries. Other acute postprocedural pain

Interventions

Intervention 1: In the intervention group, immediately before induction of anesthesia, intrathecally received 0.2 micrograms per kilogram of weight of sufentanil (Caspian or Aburihan) and did not rece

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Adults who are between 18-75 years old Informed consent for participation in project Candidate for gastrointestinal cancers surgeries

Exclusion criteria

Exclusion criteria: No addiction No history af allergy to sufentanil or other drugs

Design outcomes

Primary

Measure	Time frame
Pain score in pain numerical scale. Timepoint: At the beginning of surgery and every twenty minutes until the end of surgery. Method of measurement: Pain numerical scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Alireza Bameshki

Mashhad University of Medical Sciences

bameshkiar@mums.ac.ir0098513858387

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026